Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Anne Fenton"'
Autor:
Guochun Jiang, Erica A Mendes, Philipp Kaiser, Daniel P Wong, Yuyang Tang, Ivy Cai, Anne Fenton, Gregory P Melcher, James E K Hildreth, George R Thompson, Joseph K Wong, Satya Dandekar
Publikováno v:
PLoS Pathogens, Vol 11, Iss 7, p e1005066 (2015)
Although anti-retroviral therapy (ART) is highly effective in suppressing HIV replication, it fails to eradicate the virus from HIV-infected individuals. Stable latent HIV reservoirs are rapidly established early after HIV infection. Therefore, effec
Externí odkaz:
https://doaj.org/article/b2ad6307e0f0458da03b9910c3f96008
Autor:
Angela Sena, Irina Grishina, Anne Thai, Larissa Goulart, Monica Macal, Anne Fenton, Jay Li, Thomas Prindiville, Sonia Maria Oliani, Satya Dandekar, Luiz Goulart, Sumathi Sankaran-Walters
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e76969 (2013)
BACKGROUND:Development of inflammatory bowel disease (IBD) involves the interplay of environmental and genetic factors with the host immune system. Mechanisms contributing to immune dysregulation in IBD are not fully defined. Development of novel the
Externí odkaz:
https://doaj.org/article/f47cefd0e4ac42909e013259f5d93f4a
Publikováno v:
Current Oncology, Vol 30, Iss 12, Pp 10211-10223 (2023)
Antibody drug conjugates (ADCs) have emerged as a highly effective treatment strategy across breast cancer (BC) subtypes, including human epidermal growth factor receptor 2-positive (HER2+), hormone-receptor positive (ER/PR+), and triple-negative bre
Externí odkaz:
https://doaj.org/article/11ae706ced044892a413cd9ac79afd1b
Autor:
Chaohui Lisa Zhao, Kamaljeet Singh, Alexander S. Brodsky, Shaolei Lu, Theresa A. Graves, Mary Anne Fenton, Dongfang Yang, Ashlee Sturtevant, Murray B. Resnick, Yihong Wang
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
Abstract Background The breast cancer microenvironment contributes to tumor progression and response to chemotherapy. Previously, we reported that increased stromal Type X collagen α1 (ColXα1) and low TILs correlated with poor pathologic response t
Externí odkaz:
https://doaj.org/article/f91ad71a403846a2922564339a7eac6e
Autor:
Lyndsay N. Harris, William Sikov, Mary Anne Fenton, Maysa M. Abu-Khalaf, George Somlo, Veerle Bossuyt, Eric P. Winer, Ian E. Krop, Amad Awadallah, Shikha Parsai, David Tuck, Kristy L.S. Miskimen, Hannah Gilmore, Vinay Varadan
Supplemental Figure 1. Consort Diagram 03-311. Supplemental Figure 2. Consort Diagram 211B. Supplemental Figure 3. Subtype-specific changes in Immune Index upon brief-exposure to nab-paclitaxel in the 211B trial. Supplemental Figure 4. Evaluation of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21a5db4057260e4562d3b1ce51541679
https://doi.org/10.1158/1078-0432.22456575.v1
https://doi.org/10.1158/1078-0432.22456575.v1
Autor:
Lyndsay N. Harris, William Sikov, Mary Anne Fenton, Maysa M. Abu-Khalaf, George Somlo, Veerle Bossuyt, Eric P. Winer, Ian E. Krop, Amad Awadallah, Shikha Parsai, David Tuck, Kristy L.S. Miskimen, Hannah Gilmore, Vinay Varadan
Purpose: Recent data suggest that intrinsic subtype and immune cell infiltration may predict response to trastuzumab-based therapy. We studied the interaction between these factors, changes in immune signatures following brief exposure to trastuzumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c37301986569ddb50dbd760168b8c62
https://doi.org/10.1158/1078-0432.c.6523356
https://doi.org/10.1158/1078-0432.c.6523356
Autor:
Christine M Emmick, Ashley Stuckey, Marlene Cutitar, Jennifer Gass, Sabrina M Witherby, Robert D. Legare, Mary Anne Fenton, William M. Sikov, Mary L Lopresti, Rochelle Strenger, Jessica J Bian, Theresa A. Graves, David A Edmondson, Sonali V Pandya, Bachir J. Sakr, Donald S Dizon, Adam J. Olszewski
Publikováno v:
Breast Cancer Research and Treatment. 189:93-101
In HER2-positive breast cancer (HER2+ BC), neoadjuvant chemotherapy (NACT) with dual HER2-targeted therapy achieves high pathologic complete response (pCR) rates. Anthracycline-free NACT regimens avoid toxicities associated with anthracyclines, but e
Publikováno v:
Cancer Research. 81:PS7-57
For patients who complete treatment for breast cancer, national oncologic guidelines recommend yearly mammography surveillance and oncology follow-up especially during the first five years of survivorship. Some studies have shown that older age and i
Autor:
David A Edmondson, Sonali V Pandya, Marlene Cutitar, Ashley Stuckey, Rochelle Strenger, Don S. Dizon, Sabrina M Witherby, Bachir J. Sakr, William M. Sikov, Mary Anne Fenton, Jennifer Gass, Mary L Lopresti, Robert D. Legare, Theresa A. Graves, Christine M Emmick, Adam J. Olszewski, Jessica J Bian
Publikováno v:
Cancer Research. 80:P2-16
In H+BC, neoadjuvant chemotherapy (NACT) with dual HER2-targeted therapy achieves high pathologic complete response (pCR) rates, but the most common anthracycline-free regimen, every 3-week docetaxel and Cb with T and P (TCHP), causes significant hem
Publikováno v:
Cancer Research. 80:P2-13
Background: The prognosis of patients with estrogen receptor positive (ER+) bone-only metastatic breast cancer (B-MBC) is good, with the average life expectancy extending years with contemporary management. In the general population, studies investig